Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warfarin Labeling Change: Genetic Test Firms Anxiously Await FDA Action

This article was originally published in The Gray Sheet

Executive Summary

Genetic test makers are lining up in anticipation of an FDA label change for the blood thinner warfarin that could significantly expand the market for companion diagnostics. They might still have a while to wait

You may also be interested in...



Personalized Genetic Test Info Added To Warfarin Drug Labeling

FDA is updating the label for the anti-clotting drug warfarin to inform physicians and patients about the usefulness of genetic testing before beginning therapy, but the agency will wait for data from ongoing studies of the tests before adding stronger recommendations for the tests

Personalized Genetic Test Info Added To Warfarin Drug Labeling

FDA is updating the label for the anti-clotting drug warfarin to inform physicians and patients about the usefulness of genetic testing before beginning therapy, but the agency will wait for data from ongoing studies of the tests before adding stronger recommendations for the tests

C-Path Institute Exec Targets “Points Of Pain” In Device Development

The Critical Path Institute's new Director of Medical Devices and Imaging, Ellen Feigal, MD, is working with device firms to identify key roadblocks to product development and clear the way to regulatory approval for those products

Related Content

UsernamePublicRestriction

Register

MT025139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel